The C-MIC-II Follow-Up Study

NCT ID: NCT05189860

Last Updated: 2025-06-08

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

RECRUITING

Clinical Phase

NA

Total Enrollment

31 participants

Study Classification

INTERVENTIONAL

Study Start Date

2022-03-03

Study Completion Date

2026-11-15

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

The C-MIC System is a medical device used to treat heart failure per the intended purpose which is to treat heart failure by applying an electrical micro-current to the heart.

Target patients for this study are patients who have received the device in a prior study.

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

The C-MIC System is a medical device used to treat heart failure per the intended purpose which is to treat heart failure by applying an electrical micro-current to the heart. The therapy with the C-MIC System is intended to take 6 months.

The C-MIC System consists of four parts, of which three are implanted: a transvenous and an epicardial lead and a power source to which the leads are connected. Both leads have the function to transmit micro-current to the heart. A Portable User Terminal (PUT) is needed for programming and readout of the data recorded by the Implantable Microcurrent Device (IMD).

Target patients of the C-MIC System at the time of implantation and inclusion in the C-MICII Study were patients with idiopathic dilative cardiomyopathy (NYHA class III - NYHA class who have systolic left ventricular dysfunction despite adequate therapy of heart failure.

Target patients for this study are patients who have received the device in a prior study.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Systolic Left Ventricular Dysfunction

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

NA

Intervention Model

SINGLE_GROUP

Study objective is to assess the safety of the C-MIC System in case of system extended use or abandonment or explantation in patients having received a C-MIC System in the context of a prior study.
Primary Study Purpose

TREATMENT

Blinding Strategy

NONE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

C-MIC Device

Device plus Standard of Care

Group Type EXPERIMENTAL

C-MIC system

Intervention Type DEVICE

This study aims to follow up patients already treated with a C-MIC System over a period of 2 years following the initial treatment with the device, to assess the long term results.

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

C-MIC system

This study aims to follow up patients already treated with a C-MIC System over a period of 2 years following the initial treatment with the device, to assess the long term results.

Intervention Type DEVICE

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Patients who have received a C-MIC System during the C-MIC-II Study.
* Informed consent in writing from the patient.

Exclusion Criteria

* Patients who are unwilling or unable to participate in the study visits.
* Vulnerable Patients.
Minimum Eligible Age

18 Years

Maximum Eligible Age

75 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

Berlin Heals GmbH

INDUSTRY

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Responsibility Role SPONSOR

Principal Investigators

Learn about the lead researchers overseeing the trial and their institutional affiliations.

Peter Goettel, MD

Role: STUDY_CHAIR

Berlin Heals GmbH

Locations

Explore where the study is taking place and check the recruitment status at each participating site.

University Clinical Centre of Republic of Srpska

Banja Luka, Banja Luka, Bosnia and Herzegovina

Site Status NOT_YET_RECRUITING

University Clinical Center of Sarajevo

Sarajevo, Sarajevo, Bosnia and Herzegovina

Site Status NOT_YET_RECRUITING

Clinical Hospital Dubrava

Zagreb, City of Zagreb, Croatia

Site Status RECRUITING

University Clinic Cardiac Surgery

Skopje, , North Macedonia

Site Status RECRUITING

Clinical Center of Serbia

Belgrade, , Serbia

Site Status RECRUITING

Clinical Hospital Center Bezanijska Kosa

Belgrade, , Serbia

Site Status RECRUITING

Countries

Review the countries where the study has at least one active or historical site.

Bosnia and Herzegovina Croatia North Macedonia Serbia

Central Contacts

Reach out to these primary contacts for questions about participation or study logistics.

Peter Goettel, MD

Role: CONTACT

+49 30 88913640 ext. 61

Kersten Brandes, MD

Role: CONTACT

+49 30 88913640 ext. 66

Facility Contacts

Find local site contact details for specific facilities participating in the trial.

Igor Rudez, MD

Role: primary

Related Links

Access external resources that provide additional context or updates about the study.

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

C-MIC-II-FU

Identifier Type: -

Identifier Source: org_study_id

More Related Trials

Additional clinical trials that may be relevant based on similarity analysis.

CardioInsight 1 RBBB
NCT05555966 UNKNOWN NA